国: オーストリア
言語: 英語
ソース: HMA (Heads of Medicines Agencies)
cefalexin monohydrate 300 mg
LABORATOIRE SOGEVAL
QJ01DB01
Tablet
Cefalexin
Dogs
2009-11-25
Revised 29/03/2010 – AN 02535/2008 1. NAME OF THE VETERINARY MEDICINAL PRODUCT UK, AT, IE, PL, CZ, BE, HU, GK, LUX, NL, PT Therios 300 mg palatable tablets for dogs IT, ES, FI Therios 300 mg flavoured tablets for dogs DE Therios 300 mg aromatisierte Tabletten für Hunde 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Each tablet contains: Cefalexin (as cefalexin monohydrate) .........................................300 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Round scored beige palatable tablet The tablet can be divided into equal halves and quarters 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of bacterial skin infections in dogs (including deep and superficial pyoderma) caused by organisms sensitive to cefalexin. For the treatment of urinary tract infections in dogs (including nephritis and cystitis) caused by organisms sensitive to cefalexin. 4.3 CONTRAINDICATIONS Do not use in animals which are known to be hypersensitive to penicillins. Do not use in case of severe renal failure Do not use in rabbits, guinea pigs, hamsters and gerbils. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS As with other antibiotics which are excreted mainly by the kidneys, systemic accumulation may occur when renal function is impaired. In case of known renal insufficiency the dose should be reduced. The product is not recommended for use in dogs less than 2.5 kg bodyweight. Wherever possible, the u 完全なドキュメントを読む